Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
A phase 1 trial of ISB 2001 in Multiple myeloma, run by Ichnos Sciences SA, now recruiting.
Overview
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) is a phase 1 interventional study registered as NCT05862012 by Ichnos Sciences SA, with 200 participants planned, started 2023-11-01 and due to reach its primary completion in 2027-07. Interventions recorded: ISB 2001, ISB 2001. Conditions recorded: Relapsed/Refractory Multiple Myeloma.
Linked to the drug ISB 2001 because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Shares Multiple myeloma and the tag pipeline.
- TrialPamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSiltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Shares Multiple myeloma and the tag pipeline.
- TrialGeriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
Shares Multiple myeloma and the tag pipeline.